Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

3479 - A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial.

Date

09 Sep 2017

Session

Breast cancer, metastatic

Presenters

Yeon Hee Park

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

Y.H. Park1, K. Lee2, J. Sohn3, K.S. Lee4, K.H. Jung5, J.H. Kim6, K.H. Lee7, J.S. Ahn1, T. Kim2, G.M. Kim3, I.H. Park4, S. Kim5, S.H. Kim6, H.S. Han7, Y. Im1, J.H. Ahn5, J. Kim8, J. Kang9, S. Im2

Author affiliations

  • 1 Division Of Hematology-oncology, Departments Of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 2 Section Of Hematology & Oncology, Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 3 Department Of Internal Medicine, Yonsei Cancer Center, 120-752 - Seoul/KR
  • 4 Center For Breast Cancer, National Cancer Center Hospital, 410-769 - Goyang/KR
  • 5 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 6 Department Of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 463-707 - Seongnam/KR
  • 7 Department Of Internal Medicine, Chungbuk National University Hospital, 361-711 - Cheongju/KR
  • 8 Clinical Development Division, National OncoVenture, Goyang/KR
  • 9 Clinical Research And Development, Hanmi Pharmaceutical Co., Ltd., Seoul/KR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3479

Background

Although the introduction of HER2 directed therapy including trastuzumab, pertuzumab, lapatinib, and TDM-1 in the treatment of HER2-positive metastatic breast cancer (mBC) patients favorably changed the natural history of this disease, HER2-positive mBC will eventually progress in most patients. Poziotinib is a novel, oral pan-HER kinase inhibitor which showed potent anti-tumor activities through irreversible inhibition of HER family tyrosine kinases.

Methods

This open-label, multicenter phase 2 study was designed to evaluate the efficacy and safety of poziotinib monotherapy in patients with HER2-positive mBC who have progressed from more than 2 HER2-directed therapies. Patients received poziotinib 12 mg once daily on a 14-day on/7-day off schedule. Dose escalation up to 16 mg was allowed at appropriate time point and dose reduction to 8-10 mg were performed according to toxicities. Progression-free survival (PFS) as the primary endpoint and objective response rate (ORR), overall survival (OS), and safety were evaluated.

Results

From Apr 2015 to Feb 2016, 106 patients were enrolled in the trial from 7 institutes in Korea. The patients were median age of 50 (range: 30∼76) who had received median 4 prior anti-cancer therapies including median 2 HER2-directed therapies in the advanced or metastatic setting. Median follow up duration was 12 months. The median PFS was 4.04 months (95% CI, 2.94 - 4.40 months), and median overall survival has not been reached. The disease control rate was 75.49% (77/102) including 20 patients with confirmed partial response. The most common treatment-related AEs were (total/grade≥3) diarrhea (96.23%/14.15%), stomatitis (92.45%/12.26%), and rash (63.21%/3.77%).

Conclusions

Poziotinib showed meaningful clinical activity in heavily-treated HER2-positive mBCs. Diarrhea and stomatitis were the major toxicities leading to dose modification. Biomarker study being analyzed from pre- and on-treatment biopsies is warranted to support further on the meaningful clinical outcomes of poziotinib in HER2-positive mBC.

Clinical trial identification

NCT02418689

Legal entity responsible for the study

National OncoVenture & Hanmi Pharmaceutical Co., Ltd.

Funding

Hanmi Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.